News

Eli Lilly: If You Don't Buy On Weight Loss Promise Now, You Probably Never Will
Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...
1 Underrated Reason to Buy This Market-Beating Stock
Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...
Seeking Alpha5y
Eli Lilly Shows Its Strength With Taltz In Positive Head To Head Study
The phase 4 study is known as IXORA-R. This study was a head to head study between Taltz and Tremfya. There were a total of 1,027 patients with moderate to severe plaque psoriasis. The primary ...
Business Insider7y
Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area
INDIANAPOLIS, May 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz ® (ixekizumab ...
Zacks Investment Research on MSN23d
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales. Sales of ...
Ibj.com8y
Eli Lilly chasing psoriasis jackpot with Taltz
The minute-long commercial, featuring lots of bare shoulders, midriffs and swimsuits, promotes a new drug by Eli Lilly and Co. called Taltz that treats red, scaly patches of skin caused by ...
FiercePharma5y
Eli Lilly's Taltz beats Novartis to the punch with FDA approval in spondyloarthritis
Eli Lilly's Taltz and Novartis' Cosentyx have been jockeying for IL-17 inhibitor supremacy with back-and-forth FDA approvals for years. But in the race for a fourth indication, Taltz has come out ...
FiercePharma5y
Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data
Eli Lilly courts physicians with blockbuster-topping Taltz data In the June data presentation, 36% of patients treated with Taltz hit both markers at 24 weeks, topping Humira, which saw only 28% ...
Business Insider5y
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS, Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz ® (ixekizumab) injection 80 mg/mL ...
Yahoo Finance5y
Eli Lilly’s Taltz Injection Gets FDA Nod For Inflammatory Spine Arthritis Treatment
Drugmaker Eli Lilly & Co (LLY) said that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (BLA) for its Taltz injection used for the treatment ...
Ibj.com5y
Lilly’s hot-selling Taltz approaching blockbuster status
Two decades ago, Eli Lilly and Co. boasted just one ... While many new products are fueling Lilly’s turnaround, Taltz, launched in 2016, is an especially key driver. The company spent hundreds ...
Monthly Prescribing Reference9y
Taltz Approved for Moderate-to-Severe Plaque Psoriasis
Eli Lilly announced that the Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for ...